Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cadus Pharmaceutical Corp. (KDUS) -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (771)	4/9/2002 9:13:11 AM
From: scaram(o)uche	Read Replies (1) \| Respond to of 1833

Tuesday April 9, 7:04 am Eastern Time Press Release SOURCE: Axiom Biotechnologies Inc. Axiom Biotechnologies Inc. Announces Collaboration with Sosei Co., Ltd. to Identify New Indications for Drug Candidates SAN DIEGO--(BW HealthWire)--April 9, 2002--Axiom Biotechnologies Inc. announced today that it has entered into a collaboration with Sosei Co., Ltd. to use its physiogenomics technology to identify new indications for drug candidates from Sosei's drug re-profiling platform (DRP) collection. Sosei has assembled a library of drug candidates that have already demonstrated acceptable safety profiles in clinical trials, surmounting a major barrier to successful drug discovery. Some of these compounds are marketed drugs in Japan that have never been exposed to the major Western countries, others stumbled late in clinical trials over efficacy issues. Axiom will profile these compounds for clinically relevant activities using its physiogenomics approach, which produces high-definition data on compound function in a broad array of human cell types. Once a relevant activity has been confirmed, the compound can rapidly move into clinical development since its safety profile has already been established. ``This collaboration with Sosei highlights one of the major strengths of our physiogenomics technology, its ability to rapidly establish the functions of drug candidates in native human cells representing all of the major tissues of the body,'' said Dr. Michael Kozlowski, Axiom's COO. ``Using our technology to develop new applications for drug candidates or even marketed drugs is one component of our business strategy.'' Mr. Kenzo Nakajima, Executive Vice President and Chief Operating Officer of Sosei, said: ``Our collaboration with Axiom is very important for us and will strongly supplement our DRP consortium consisting of selected Western biotech companies with each having unique proprietary drug discovery techniques. Sosei has already discovered novel indications of several compounds in collaboration with the existing DRP consortium members. We have completed feasibility clinical studies for one of them and are now under preparation of patent filing for another compound. We hope Axiom will provide us with a particularly efficient approach to identify novel indications for our products through their proprietary physiogenomics technology.'' The term of the collaboration is two years, but it can be extended by mutual consent. The financial terms of the agreement were not disclosed. Sosei is a leading private Japanese biopharmaceutical company focused on drug development, developing its core product pipeline via in-licensing compounds at late-stages of development, by its distinctive DRP and through its internal R&D programs in collaboration with biopharmaceutical companies and universities both in Japan and the West. The company is capitalizing on its extensive global network established over the past ten years. For further information about Sosei, please visit www.sosei.com. Axiom Biotechnologies is a privately-held biopharmaceutical company focused on the more rapid production of drugs that are more effective and safer, through the application of its proprietary physiogenomics approach. This approach incorporates Axiom's Human Cell Bank, a large collection of pharmacologically and genetically characterized human cells, as well as proprietary cell assay technologies. Axiom's headquarters are located at 3550 General Atomics Court, San Diego, CA 92121. Axiom's telephone number is (858) 455-4500. On the internet please refer to our website: axiombio.com. -------------------------------------------------------------------------------- Contact: Axiom Biotechnologies Inc. Pandi Veerapandian, CEO / Michael R. Kozlowski, COO / Robert Lorifice, VP Finance all of Axiom Biotechnologies Inc. 858/455-4500 www.axiombio.com